Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Complementary Medicines
Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Rheumatology (Oxford) ; 51(11): 1953-65, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22843790

ABSTRACT

OBJECTIVE: To assess the effects of epigallocatechin-3-gallate (EGCG) on cytokine-induced Cyr61 synthesis in human osteoblastic cells and the associated signalling pathways. The therapeutic effect of EGCG on CIA in rats was also studied. METHODS: The expression of Cyr61 and NF-κB pathway molecules was examined by western blotting. CCL2 expression was assessed by northern blotting and ELISA. Interaction between NF-κB and Cyr61 promoter was evaluated by electrophoretic mobility shift assay. In rat CIA, osteoblastic expression of Cyr61 was examined by immunohistochemistry and disease progression was assessed by clinical, radiographic and histological examinations. RESULTS: EGCG inhibited Cyr61 expression stimulated by cytokines in primary human osteoblasts and human osteoblastic cell line U2OS. In U2OS, oncostatin M (OSM) induced IκB-α degradation through the mTOR/rictor/Akt pathway, and EGCG attenuated the action. Electrophoretic mobility shift assay revealed that the OSM-enhanced NF-κB/DNA binding was reduced by EGCG, possibly through abrogating nucleus localization of p65 and p50. Cyr61 enhanced OSM-induced expression of CCL2. Moreover, EGCG diminished OSM-stimulated CCL2 expression at least partially via suppressing Cyr61 induction. Co-distribution of CD68(+) macrophages and Cyr61(+) osteoblasts in osteolytic areas was obvious in the CIA model. Clinical, radiographic and immunohistochemical analyses revealed that administration of EGCG markedly diminished the severity of CIA, macrophage infiltration, and the number of Cyr61-synthesizing osteoblasts. CONCLUSION: By modulating the mTOR/rictor/Akt/NF-κB pathway, EGCG attenuated Cyr61 production in osteoblastic cells and in turn diminished macrophage chemotaxis. Our data support the therapeutic potential of EGCG on arthritis.


Subject(s)
Arthritis/therapy , Catechin/analogs & derivatives , Cysteine-Rich Protein 61/biosynthesis , Cytokines/pharmacology , Osteoblasts/metabolism , Adult , Animals , Arthritis/metabolism , Catechin/pharmacology , Cells, Cultured , Chemokine CCL2/metabolism , Chromones/pharmacology , Cysteine-Rich Protein 61/drug effects , Enzyme Inhibitors/pharmacology , Humans , Inositol Phosphates/pharmacology , Male , Morpholines/pharmacology , NF-kappa B/drug effects , NF-kappa B/metabolism , Rats , Rats, Sprague-Dawley , Signal Transduction , Sirolimus/pharmacology , TOR Serine-Threonine Kinases/antagonists & inhibitors , Young Adult
2.
J Endod ; 35(2): 206-11, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19166774

ABSTRACT

Recent investigations indicate that epigallocatechin-3-gallate (EGCG), the major polyphenol of green tea, has anti-inflammatory properties. This study assessed the effect of EGCG on oncostatin M (OSM)-induced synthesis of cysteine-rich 61 (Cyr61), a potential osteolytic mediator, in MG-63 human osteoblastic cells. The therapeutic effect of EGCG in apical periodontitis in rats was also examined. Western blot analysis showed that OSM stimulated Cyr61 synthesis in MG-63 in a time-dependent manner, whereas EGCG readily attenuated this effect. On the other hand, Cyr61 treatment of MG-63 cells induced the release of CCL2, a chemokine responsible for macrophage chemotaxis. In a rat model of induced apical periodontitis, radiography and histopathology revealed that administration of EGCG markedly diminished the severity of periapical lesions. The numbers of Cyr61-synthesizing osteoblasts and infiltrating macrophages were also decreased. Thus, EGCG suppresses the progression of apical periodontitis, possibly by diminishing Cyr61 expression in osteoblasts and, subsequently, macrophage chemotaxis into the lesions.


Subject(s)
Antioxidants/therapeutic use , Catechin/analogs & derivatives , Cysteine-Rich Protein 61/antagonists & inhibitors , Osteoblasts/drug effects , Periapical Periodontitis/drug therapy , Plant Extracts/therapeutic use , Tea , Alveolar Bone Loss/drug therapy , Animals , Antioxidants/pharmacology , Catechin/pharmacology , Catechin/therapeutic use , Cell Line, Tumor , Chemokine CCL2/biosynthesis , Chemotaxis, Leukocyte/drug effects , Disease Models, Animal , Humans , Oncostatin M/metabolism , Osteoblasts/metabolism , Plant Extracts/pharmacology , Rats , Rats, Wistar , Tea/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL